Founded in 2022 by Daniel Teper and headquartered in Aventura, Florida, Cytovia Therapeutics aims to provide faster patient access to transformative cell therapies and immunotherapies, focusing on harnessing the innate immune system. They are developing three types of iPSC-derived Natural Killer cells, including gene-edited iNK cells with improved function and persistence, as well as CAR-iNKs for tumor-specific targeting. Additionally, they have a multispecific antibody platform designed to engage natural killer cells. Cytovia is targeting solid tumors like hepatocellular carcinoma and glioblastoma, along with hematological malignancies such as refractory multiple myeloma. They have research and manufacturing facilities in Massachusetts and Puerto Rico, and collaborate with renowned scientific institutions. Recently, they formed CytoLynx Therapeutics, a joint-venture entity focused on research, manufacturing, and commercialization in Greater China and beyond. For more information, visit www.cytoviatx.com.